Merck's (MRK +0.2%) and Bristol-Myers Squibb's (BMY +0.7%) multi-billion dollar diabetes drugs...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Merck's (MRK +0.2%) and Bristol-Myers Squibb's (BMY +0.7%) multi-billion dollar diabetes drugs could double the risks of patients developing pancreatitis, which is an inflammation of the pancreas, a study indicates. Merck's Januvia and Bristol-Myers' Byetta increase GLP-1, a hormone that stimulates the pancreas' insulin output. Other drugs that do the same but weren't in study include Bristol's Onglyza and Novo Nordisk's (NVO) Victoza.